Dr. Wisinski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
600 Highland Ave
Madison, WI 53792Phone+1 608-265-1700Fax+1 608-266-6020- Is this information wrong?
Summary
- Dr. Kari Wisinski is a professor and breast medical oncologist at the University of Wisconsin (UW) Carbone Cancer Center and Chief of the Division of Hematology, Medical Oncology and Palliative Care, UW School of Medicine and Public Health. She is experienced in clinical research and leads the UWCCC Breast Cancer Clinical Research team and is engaged in the BigTen Cancer Research Consortium.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
University of ColoradoResidency, Internal Medicine, 2001 - 2004
Washington University in St. Louis School of MedicineClass of 2001
Certifications & Licensure
WI State Medical License 2008 - 2025
IL State Medical License 2005 - 2017
CO State Medical License 2003 - 2005- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Interim Chief of Hematology, Medical Oncology and Palliative Care UW School of Medicine and Public Health, 2020
- Vice chair, then Chair BigTen Cancer Research Consortium Steering Committee 2018-2020
- Breast Disease Oriented Team Co-Leader UWCCC, 2017-2020
- Join now to see all
Clinical Trials
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Start of enrollment: 2016 Jun 30
- Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR Start of enrollment: 2017 May 03
- Join now to see all
Publications & Presentations
PubMed
- Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.Roisin M Connolly, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell, John J Wright, Elad Sharon, Robert J Gray, Lisa M McShane, Larry V Rubinstein, David ...> ;Clinical Cancer Research. 2024 Apr 1
- 1 citationsIs the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?Marina N Sharifi, Ruth M O'Regan, Kari B Wisinski> ;Clinical Breast Cancer. 2023 Dec 1
- 8 citationsRandomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Hum...Kevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, Prabhjot S Mundi, Elizabeth Sakach, Claire Sathe, Heejoon Ahn, Meghna S Trivedi, Yelena Novik, Amy Tiersten, Geor...> ;Journal of Clinical Oncology. 2023 Aug 20
- Join now to see all
Press Mentions
Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer SymposiumNovember 19th, 2021
Protecting Cancer Patients on High Doses of OpioidsMarch 18th, 2020
Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast CancerOctober 7th, 2019- Join now to see all
Committees
- Member, NCI Early Phase CIRB
Professional Memberships
- Member
- ECOG/ACRINMember
Hospital Affiliations
University HospitalMadison, Wisconsin
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
